FDA lifts BioDante GVAX Prostate Vax hold; Merck, Intercell stop V710 staph infection trial;

Vaccine Research

The FDA has lifted its clinical hold of BioSante's GVAX Prostate Cancer Vaccine. The company is planning a Phase II clinical trial based at Johns Hopkins Kimmel Cancer Center. BioSante release

Merck and Intercell have halted their trial of V710, a staph infection as data showed patients receiving the vaccine were more likely to die. The companies stated that the higher risk was not statistically significant. News

Medicago's Phase I trial of its plant-based seasonal flu vaccine produced positive results, according to the company. Preliminary results show that 98 percent of immunized patients developed an H1N1 immune response. Story

The Juvenile Diabetes Research Foundation will provide milestone-based financial support for Selecta Bioscience's efforts to develop a therapeutic type 1 diabetes vaccine. The vaccine will use Selecta's Synthetic Vaccine Particle technology. Item

Worcester, MA-based RXi Pharmaceuticals released positive three-year Phase II data for NeuVax, its breast cancer vaccine candidate. Patients treated with the vaccine had no recurrences of breast cancer 36 months after vaccination, but control group patients had a 22 percent recurrence rate. Report

Vaccine Market

Cellectis BioResearch and VitamFero have signed a five-year research deal to focus on parasitic infection vaccines. VitamFero will have access to Cellectis' meganuclease technology for its work on live attenuated vaccines. Cellectis release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.